Risk Factors for Psychosis
Paradigms, Mechanisms, and Prevention
- 1st Edition - February 22, 2020
- Imprint: Academic Press
- Editors: Andrew Thompson, Matthew Broome
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 1 3 2 0 1 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 1 3 2 0 2 - 9
Risk Factors for Psychosis: Paradigms, Mechanisms, and Prevention combines the related, but disparate research endeavors into a single text that considers all risk factors f… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteRisk Factors for Psychosis: Paradigms, Mechanisms, and Prevention combines the related, but disparate research endeavors into a single text that considers all risk factors for psychosis, including biological, psychological and environmental factors. The book also introduces the ethics and current treatment evidence that attempts to ameliorate risk or reduce the number of individuals with risk factors developing a psychotic disorder. Finally, the book highlights new research paradigms that will further enhance the field in the future.
Psychotic disorders affect more than 50 million people worldwide, creating a devastating effect on lives and causing major financial and emotional impact on families and on society as a whole. The search for risk factors for psychosis has developed rapidly over the past decades, invigorated by changes in the thinking about the malleability and treatability of psychotic disorders. The paradigms for investigating psychosis risk have developed, often in parallel, but there has been no book to date that has summarized and synthesized the current approaches.
- Integrates research from biological, psychological and environmental factors into a single resource
- Offers insight into at-risk paradigms, biomarkers, and the current state of research on treatment option for psychosis
- Presents a holistic and dynamic look at risk syndromes and how they can be measured through neuroimaging, neuropsychology and other methods
Advanced students, postgraduate students, researchers, and clinicians in neuroscience, biological psychiatry, and psychology
1. Historical perspectives on psychosis risk
CRISTINA MEI AND PATRICK D. MCGORRY
2. Principles of risk, screening, and prevention in psychiatry
EMMA SONESON, JESUS PEREZ, AND PETER B. JONES
I - Risk paradigms
3. At-risk mental states
ALISON R. YUNG
4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbances
FRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL €UCKIGER, AND ANASTASIA THEODORIDOU
5. Schizotypy, schizotypal personality, and psychosis risk
NEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL
6. Familial high risk and high-risk studies
LIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE
7. Psychotic-like experiences in the general population
COLM HEALY AND MARY CANNON
8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosis
CORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDO
II - Specific areas and risk
9. Neuroimaging studies in people at clinical high risk for psychosis
GEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE
10. Genetic studies of psychosis
HANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS
11. Immune processes and risk of psychosis
ADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK
12. Neurochemical models of psychosis risk and onset
DOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE
13. Clinical risk factors for psychosis
ASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON
14. Cognitive risk factors for psychosis
KELLY ALLOTT AND ASHLEIGH LIN
15. Society and risk of psychosis
CRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON
16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?
MARCO COLIZZI AND SAGNIK BHATTACHARYYA
III - Interventions
17. The ethics of identifying and treating psychosis risk
PAOLO CORSICO AND ILINA SINGH
JEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY
19. Pharmacological intervention for people at risk of psychotic disorder
E. BURKHARDT, K. LEOPOLD AND A. BECHDOLF
20. International services for assessing and treating psychosis risk
CHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN
21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic prediction
RACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON
22. Future directions in risk research
NIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT
CRISTINA MEI AND PATRICK D. MCGORRY
2. Principles of risk, screening, and prevention in psychiatry
EMMA SONESON, JESUS PEREZ, AND PETER B. JONES
I - Risk paradigms
3. At-risk mental states
ALISON R. YUNG
4. Subjective disturbances in emerging psychosis: basic symptoms and self-disturbances
FRAUKE SCHULTZE-LUTTER, CHANTAL MICHEL, RAHEL FL €UCKIGER, AND ANASTASIA THEODORIDOU
5. Schizotypy, schizotypal personality, and psychosis risk
NEUS BARRANTES-VIDAL, ANNA RACIOPPI, AND THOMAS R. KWAPIL
6. Familial high risk and high-risk studies
LIANA ROMANIUK, STELLA W.Y. CHAN, ALIX MACDONALD, JESSIKA E. SUSSMANN, ANDREW M. MCINTOSH, HEATHER C. WHALLEY, AND STEPHEN M. LAWRIE
7. Psychotic-like experiences in the general population
COLM HEALY AND MARY CANNON
8. 22q11.2 deletion syndrome: a neurodevelopmental model of psychosis
CORRADO SANDINI, STEPHAN ELIEZ, MAUDE SCHNEIDER, AND MARCO ARMANDO
II - Specific areas and risk
9. Neuroimaging studies in people at clinical high risk for psychosis
GEORGE GIFFORD, ROB MCCUTCHEON, AND PHILIP MCGUIRE
10. Genetic studies of psychosis
HANNAH J. JONES, STANLEY ZAMMIT, AND JAMES T.R. WALTERS
11. Immune processes and risk of psychosis
ADAM AL-DIWANI AND THOMAS ARTHUR NICHOLLS POLLAK
12. Neurochemical models of psychosis risk and onset
DOMINIC OLIVER, GEMMA MODINOS, AND PHILIP MCGUIRE
13. Clinical risk factors for psychosis
ASWIN RATHEESH, JESSICA A. HARTMANN, AND BARNABY NELSON
14. Cognitive risk factors for psychosis
KELLY ALLOTT AND ASHLEIGH LIN
15. Society and risk of psychosis
CRAIG MORGAN, TESSA ROBERTS, BRIAN O. DONOGHUE, AND ANDREW THOMPSON
16. Is there sufficient evidence that cannabis use is a risk factor for psychosis?
MARCO COLIZZI AND SAGNIK BHATTACHARYYA
III - Interventions
17. The ethics of identifying and treating psychosis risk
PAOLO CORSICO AND ILINA SINGH
JEAN ADDINGTON, DANIJELA PISKULIC, DANIEL J. DEVOE, OLGA SANTESTEBAN-ECHARRI, AND JACQUELINE STOWKOWY
19. Pharmacological intervention for people at risk of psychotic disorder
E. BURKHARDT, K. LEOPOLD AND A. BECHDOLF
20. International services for assessing and treating psychosis risk
CHRISTY L.M. HUI, W.C. CHANG, SHERRY K.W. CHAN, EDWIN H.M. LEE, Y.N. SUEN, AND ERIC Y.H. CHEN
21. New paradigms to study psychosis risk: clinical staging, pluripotency, and dynamic prediction
RACHAEL SPOONER, JESSICA A. HARTMANN, PATRICK D. MCGORRY, AND BARNABY NELSON
22. Future directions in risk research
NIKOLAI ALBERT, LOUISE BIRKEDAL GLENTHØJ, AND MERETE NORDENTOFT
- Edition: 1
- Published: February 22, 2020
- No. of pages (Paperback): 456
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128132012
- eBook ISBN: 9780128132029
AT
Andrew Thompson
Dr Andrew Thompson is a Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, Australia. He is the lead psychiatrist for the EPPIC early psychosis service and the National headspace Early Psychosis program in Australia and is currently head of clinical psychosis research at Orygen. He also retains a position as Associate Professor at the University of Warwick in the UK.
Andrew trained in medicine at the University of Oxford and London and in psychiatry in Nottingham and Bristol. He has an MD in clinical psychiatry from the University of London. He has worked in early psychosis practice and research for over 15 years in both the UK and Australia. He was previously clinical lead for the PACE at risk for psychosis clinic in Melbourne and has been involved in a number of research projects through this clinic and through his work at the University of Bristol and the University of Warwick.
Andrew’s research interests include clinical risk factors for the development of psychosis and psychotic symptoms, novel treatments (including technology) in emerging or early psychosis, predictors of outcome in early psychosis and systems of care and prevention approaches in youth mental health.
Affiliations and expertise
Principal Research Fellow and Associate Professor at Orygen, the Centre for Youth Mental Health at the University of Melbourne, AustraliaMB
Matthew Broome
Dr Matthew Broome is a Senior Clinical Research Fellow at the Department of Psychiatry, University of Oxford, and a Consultant Psychiatrist at the Early Intervention in Psychosis Service, Oxford. He trained in medicine at the University of Birmingham and in Psychiatry at the Maudsley hospital (where he worked at the at risk for psychosis clinic (OASIS). He has previously been a Lecturer at the Institute of Psychiatry and an Associate Clinical Professor at The University of Warwick. He has previously edited books on subjects such as phenomenology and the interface between psychiatry and philosophy and has published over 100 research papers mostly relating to at risk for psychosis groups.
Affiliations and expertise
Senior Clinical Research Fellow, Department of Psychiatry, University of Oxford, UKRead Risk Factors for Psychosis on ScienceDirect